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Abstract 
There are still many things to be found out about interstitial cystitis/painful bladder syndrome (IC/PBS) because the 
pathological processes underlying the condition are not yet elucidated, biological markers of the condition are not yet available, and 
the type and severity of symptoms can vary, so, clearly defining the condition is not yet possible.  
For example, it is not clearly understood whether IC/PBS represents a systemic disease, if it is localized in the bladder, or 
if it was initially localized in the bladder and it later evolved into a systemic disease. This condition is best managed by using a 
multidisciplinary approach. Management requires a good integration and knowledge of all pelvic organ systems and other systems 
including musculoskeletal, neurologic, and psychiatric systems.  
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Introduction 
Patients with IC/PBS suffer from a “silent 
ordeal”; they often appear healthy but experience 
unrelenting pain that requires frequent trips to the 
bathroom, both day and night. They may curtail 
activities due to an extreme urinary frequency. Sleep 
deprivation caused by pain and nocturia can lead to 
fatigue and depression. Many are unable to work in 
this situation. In addition to the personal costs that 
IC/PBS exacts, the condition is associated with 
significant health care costs. Experts estimated the 
total medical expenditures associated with IC/PBS in 
the United States to be of $65.9 million in 2000 [1]. 
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Graph 1. The relationship 
between BPS/IC and 
other chronic pain 
syndromes. [3] 
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Chronic pelvic pain (known as persistent) occurs 
for at least 3 months. It is associated with changes in the 
central nervous system (CNS) that may maintain the 
perception of pain in the absence of acute injury. These 
changes may also magnify perception so that non-painful 
stimuli are perceived as painful (allodynia) and painful 
stimuli become more painful than expected (hyperalgesia) 
[2].  
Curtis Nickel reported data from the Interstitial 
Cystitis Deep Phenotyping Research Group that confirms 
the relationship of BPS/IC to other chronic pain 
syndromes. Irritable bowel syndrome was self-reported in 
38.7% of patients vs. 5.6% of controls, fibromyalgia was 
self-reported in 17.6% of patients vs. 1.7% of controls, 
and chronic fatigue syndrome in 9.4% vs. 1.1% 
respectively. No other pain condition was found in 52.4% 
of the BPS/IC patients studied [3]. 
PBS/IC includes a major slice of the “painful 
bladder” disease complex, which consists of a large group 
of patients with bladder and/or urethral and/or pelvic pain, 
irritative voiding symptoms (urgency, frequency, nocturia, 
dysuria), and sterile urine cultures. Painful bladder 
conditions with well-established causes include radiation 
cystitis, cystitis caused by microorganisms that are not 
detected by routine culture methodologies, and systemic 
disorders that affect the bladder. In addition, many 
gynecologic disorders can mimic PBS/IC [4]. 
The perception that the original term, interstitial 
cystitis, was not at all describing the clinical syndrome or 
even the pathologic findings in many cases has led to the 
current effort of reconsidering the name of the disorder 
and even the way it is positioned in the medical spectrum 
[5]. What was originally considered a bladder disease is 
now considered a chronic pain syndrome [6] that may 
begin as a pathologic process in the bladder in most but 
not all patients and, eventually, it can develop into a 
disease in a small subset of those affected that even 
cystectomy may not benefit from [7]. Its relationship to 
other chronic pelvic pain syndromes including the chronic 
pelvic pain syndrome in men (previously referred to as 
nonbacterial prostatitis) is unclear [8]. 
 
Terminology issues 
Not only has the definition of IC/PBS been 
controversial but even the name is under debate. A 
number of other names have been used to describe this 
condition, including interstitial cystitis, painful bladder 
syndrome, urethral syndrome, trigonitis, and bladder pain 
syndrome, among others. In recent years, a variety of 
groups have proposed different names, based in part on 
their beliefs about the underlying etiology of IC/CBS. 
IC was recognized as a pathologic entity during 
the 19th century. Joseph Parrish, a Philadelphia surgeon, 
described three cases of severe lower urinary tract 
symptoms in the absence of a bladder stone in an 1836 
paper and termed the disorder “tic doloureux of the 
bladder” [9]. Teichman and colleagues (2000) argue that 
this may represent the first description of IC.  
Fifty years later, Skene (1887) used the term 
interstitial cystitis to describe an inflammation that has 
“destroyed the mucous membrane partly or wholly and 
extended to the muscular parietes” in his book “Diseases 
of the Bladder and Urethra in Women”. Early in the 20th 
century, at a New England Section meeting of the 
American Urological Association, Guy Hunner reported 
the case of eight women with a history of suprapubic pain, 
frequency, nocturia, and urgency lasting for an average of 
17 years [10]. In Baltimore 1914, he documented on non-
trigonal ulcers and bladder epithelial damage associated 
with interstitial cystitis. He drew attention to the disease, 
and, the red, bleeding areas he described on the bladder 
wall came to have the pseudonym “Hunner's ulcer.”  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Hunner’s ulcer 
In 1987, the NIH-NIDDK (National Institutes of 
Diabetes and Digestive and Kidney Disease) came with 
the criteria for the diagnosis of interstitial cystitis. This was 
probably the first structured forma proposal of diagnostic 
standards in IC. 
Although it was proposed some years before, in 
2002, The International Continence Society (ICS) defined 
the term (PBS/IC) as the complaint of suprapubic pain 
related to bladder filling, accompanied by other symptoms 
such as increased daytime and night time frequency, in 
the absence of a proven urinary infection and other 
obvious pathology. At this time, the ICS stated that the 
Interstitial Cystitis is a specific diagnosis (part of PBS) and 
requires confirmation by typical cystoscopic and 
histological features. Many consultations that took place 
in the following years discussed all data that became 
available, but the terminology and algorithms remained 
unchanged until now. 
In February 2007, the Association of 
Reproductive Health Professionals and the Interstitial 
Cystitis Association held the Consensus Meeting on 
Interstitial Cystitis in Washington DC and developed 
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statements concerning the definition and nomenclature of 
the condition. In their opinion, the nomenclature of IC/PBS 
may need to change, but change should not be 
undertaken now because there is insufficient evidence to 
support it [11].  
Chronic Pelvic Pain associated with bladder 
symptoms, described more than 150 years ago, is a 
common cause of complaint for a large number of 
women. Probably, the term Bladder Pain Syndrome is the 
most accurate to describe the CPP associated with the 
bladder, but the inclusion of IC to the term (BPS/IC) has 
to be considered. Work is needed to unify terms and 
promote the use of validated diagnostic tools. 
The 2009 Guidelines of the European 
Association of Urology dedicates 90 pages to the CPP, 
without changing or improving terminology, but rather 
concentrating all definitions, diagnostic or treatment 
algorithms and lots of clinical evidence that support this 
new approach to a very old disease. 
 
Epidemiology 
Interstitial cystitis/painful bladder syndrome 
(IC/PBS) predominantly affects women, with an average 
age at onset of 40 years old. It also affects men and, in 
rare cases, children [12]. The estimated prevalence of 
IC/PBS varies considerably, depending on the criteria 
used in defining the condition and the data collection 
methods used. Epidemiological studies have used a 
variety of data collection techniques—application of 
specific diagnostic criteria, physician diagnosis, patient 
self-report, and surveying for suggestive symptoms of the 
condition—with a resulting wide range of estimated 
prevalence. The National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) (based on 
National Health and Nutrition Examination Survey III 
[NHANES III]) estimated that 1.2 million women and 
82,000 men in the United States have IC/PBS [13]. One 
study found a prevalence of IC/PBS in the general 
population of 60 per 100,000, although this is believed to 
be an underestimate [14]. Indeed, the prevalence in a 
managed care population was of 197 per 100,000 for 
women and of 41 per 100,000 for men when diagnosed 
by using ICD-9 code [15]. 
In other countries, the prevalence is of 18-
450/100.000 women (Finland), 8-16/100.000 
(Netherlands) and 4.5/100.000 (Japan) [16]. For the 
moment, there is no specific data regarding the incidence 
of this condition in Romania. 
 
 
 
 
Prevalence estimated for 100.000 persons [16] 
Netherlands  8 - 16 
Finland  18 - 450 
Japan  4.5 
Female to Male ratio  9:1  
The only definitive risk factor for IC/PBS is 
female gender: the female-to-male ratio is generally 
estimated to be of 9:1 [17]. However, in the managed care 
study mentioned before, this ratio was only of 5:1 [18]. 
Other risk factors that have been evaluated include 
heredity and previous urinary tract infection. Recent 
research suggests that heredity might play a role in the 
pathogenesis of IC/PBS. A 2004 study found that the 
prevalence of IC/PBS in females who have a first-degree 
relative with confirmed IC/PBS is of 1,431 per 100,000. In 
comparison, the prevalence rate in the general population 
is estimated to be of about 60 per 100,000 [19]. The 2004 
study also found that the prevalence of IC/PBS in first-
degree female relatives of patients with IC/PBS confirmed 
by NIDDK diagnostic criteria was 17 times higher than the 
rate in the general population [20]. Previous urinary tract 
infection has been proposed as a possible risk factor for 
IC/PBS. Current evidence does not support bacterial 
infection as a risk factor for the condition, although it 
remains possible that infection serves as a trigger in some 
patients. [21] 
Adults with a prior history of abuse or 
traumatization demonstrate hypothalamic-pituitary-
adrenal (HPA) axis abnormalities, similar to IC/PBS 
patients. Childhood sexual abuse and physical 
traumatization are associated with subsequent lifelong 
risks of chronic pain syndromes [22]. 
 
Pathology 
Although the exact cause of PBS/IC is still 
unknown, several theories exist. No single theory has 
been proven to explain the symptoms in all cases; thus, 
many consider PBS/IC to be multifactorial in nature. One 
widespread hypothesis is that the bladder lining 
(epithelium) is deficient and therefore permeable to 
urinary irritants [23]. This theory has been expanded to 
state that the bladder epithelial glycocalyx is deficient. 
In a normal bladder, large, negatively charged 
molecules called glycoproteins and glycosaminoglycans 
(GAG) line the epithelium and provide an impermeable 
barrier. This is considered the main barrier between urine 
and circulating blood. A defect in the GAG layer allows 
leakage and absorption of urinary solutes to occur, the 
major solute being potassium. Ongoing exposure of the 
bladder wall to potassium causes inflammation, tissue 
irritation and injury, mast cell degranulation, and sensory 
nerve depolarization. This process results in symptoms 
associated with PBS/IC including urinary frequency, 
urgency, and pain [24]. Recent studies suggest that mast 
cells, containing histamine-rich granules, are involved in a 
variety of neuroinflammatory diseases [25]. Mast cell 
activation and the subsequent histamine release can be 
stimulated by acetylcholine, stress, and hormonal 
fluctuations, which may, in turn, play a role in the flares 
and seasonal symptoms that often occur with PBS/IC 
(Stanford, 2001). 
Table 1. Prevalence estimated for 100.000 persons in 
different countries [15] 
For example, most patients with vulvodynia have 
a positive PST and urgency/frequency, indicating pain of 
bladder origin (IC). IC deserves far greater consideration 
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in the differential diagnosis of patients with vulvodynia 
[26]. 
An alternate hypothesis is that an initial insult to 
the bladder occurs (e.g., a urinary tract infection), which 
excites sensory nerves located in the bladder wall. This 
excitation triggers an inflammatory response, or 
neurogenic inflammation. This in turn releases the 
neuropeptide substance P, causing the release of mast-
cell mediators, histamines, leukotrienes (resulting in local 
inflammation), cell and tissue damage, and fibrosis. 
Ultimately, there is a wind-up of the nervous system with 
neuroplasticity (c-fibers) and visceral allodynia, and pain 
beyond the bladder occurs [27]. 
PBS/IC has also been theorized to be an 
autoimmune condition because some clinical features 
resemble a disorder of the immune system. Examples 
include the chronicity, the exacerbations and remissions, 
and response to immunosuppressants seen in PBS/IC. It 
also appears that PBS/IC may have a yet unexplained 
association with autoimmune diseases and pain 
syndromes such as vulvar vestibulitis, fibromyalgia, 
Hashimoto's thyroiditis, and irritable bowel syndrome [28]. 
A recent study [29] showed increased transient 
receptor potential subtype 1 vanilloid receptor in nerve 
fibers of the bladder in painful bladder syndrome and a 
correlation of the pain score with the relative density of 
transient receptor potential subtype 1 vanilloid receptor 
nerve fibers. Transient receptor potential subtype 1 
vanilloid receptor may have a role in the pathophysiology 
of painful bladder syndrome and it is a potential target for 
the novel therapeutic agents. 
Another study [30] investigated the distribution of 
TNF-related apoptosis-inducing ligand (TRAIL) and its 
receptors in bladder biopsy samples of patients 
diagnosed with interstitial cystitis and the role of TRAIL in 
the pathogenesis of interstitial cystitis. Results indicate 
that TRAIL-R4 is the predominant receptor in the 
interstitial cystitis inflammation. 
The sialic acid content of THP (Tam Horsfall 
Protein) [42], a critical component of its biological activity, 
is reduced in patients with IC. N-glycan shows reduced 
levels of high molecular weight tri- and tetra-antennary 
sialylated oligosaccharides. These results are supported 
by quantitative monosaccharide analysis of neutral and 
amino sugars in patients vs control subjects. THP was 
isolated from urine samples of 23 patients with IC and 24 
control subjects by salt precipitation. The sialic acid 
contents were measured by using 1,2-diamino-4,5-
methylene dioxybenzene-high performance liquid 
chromatography analysis. For N-glycan profiling, purified 
THP was treated with peptide: N-glycosidase F to release 
N-glycans. The purified N-glycans were labeled with 2-
aminobenzamide and were profiled by high-pH anion 
exchange chromatography (HPAEC) with fluorescence 
detection. The neutral and amino sugars were determined 
by HPAEC with pulsed amperometric detection. THP in 
patients with IC has reduced sialylation and overall 
glycosylation, and by inference, THP has a role in the 
pathophysiology of IC. 
 
Diagnosis 
Because of the lack of criteria appropriate for 
use in the clinical setting, the general approach to 
diagnosis of IC/PBS nowadays tends to be empirical. If 
other conditions can be excluded, patients with 
characteristic signs and symptoms are generally treated 
for presumed IC/PBS. In certain circumstances, some 
clinicians may choose to evaluate further, with cystoscopy 
with hydrodistention under general anesthesia, 
urodynamic studies, or lidocaine instillation.  
The potassium chloride challenge, or Parsons’ 
test, has also been used for diagnosis. This test involves 
instillation of potassium chloride into the bladder; a 
positive result is pain and reproduction of IC/PBS 
symptoms. Because it tests for epithelial permeability, the 
potassium chloride challenge is not specific for IC/PBS 
and provides a positive result in other disorders that 
involve epithelial leakage [31]. The result is positive in 
virtually all patients with radiation cystitis and bacterial 
cystitis. The test also misses up to 25 percent of patients 
with IC/PBS as defined by NIDDK criteria [32]. The 
potassium chloride challenge is not widely used because 
of the low sensitivity and specificity, and because it is a 
painful test to undergo that also requires invasive urinary 
catheterization. Nevertheless, some experts feel it may be 
helpful in the subset of patients who have minimal pain. 
The diagnosis is generally subject to more 
rigorous testing in Europe than in North America, where 
symptoms in the absence of other obvious causes seem 
to be the gold standard [33]. 
Cystometry in conscious IC patients generally 
demonstrates normal function, the exception being a 
decreased bladder capacity and hypersensitivity. Pain on 
bladder filling that reproduces the patient's symptoms is 
very suggestive of IC. 
Performing cystoscopy with the patient under 
anesthesia allows a sufficient distention of the bladder to 
afford visualization of either glomerulations or Hunner's 
ulcers. After filling it with H2O to 80 cm for 1 to 2 minutes, 
the bladder is drained and refilled. The terminal portion of 
the effluent is often blood tinged. Reinspection will reveal 
the pinpoint petechial hemorrhages that develop 
throughout the bladder after distention and, they are not 
usually seen after the examination without anesthesia 
[34].   
Bladder biopsy is necessary only if needed to 
rule out other etiologies of the patient's symptoms. 
Glomerulations are not specific for IC [35], and 
only when seen in conjunction with the clinical criteria of 
pain and frequency, can their finding be viewed as 
significant. While the presence of a Hunner's ulcer has 
been associated with pain and urinary urgency, neither 
the findings of bloody irrigating fluid nor glomerulations 
are strongly associated with any particular symptom in 
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patients in the ICDB [36]. Clinical, urodynamic, and 
cystoscopic data strongly suggest that the presence of 
glomerulations does not select out a meaningful 
difference in patients with symptoms of PBS/IC [37]. 
As for the markers, the urine antiproliferative 
factor (APF), identified by Keay, may prove to be the most 
accurate marker of PBS/IC when confirmed by other 
centers. It appears to have the highest sensitivity and 
specificity of the variety of possible markers tested and 
fits nicely into an etiologic schema [38]. 
 
New horizons in diagnosis 
An ultra-performance liquid chromatography-
mass spectrometry (UPLC-MS) based on a metabonomic 
approach was applied to identify a candidate metabolite 
with an unknown association with the interstitial cystitis 
(IC). The urinary marker of IC was identified as 
phenylacetylglutamine (PAGN) by using NMR and MS/MS 
analysis. In addition, quantitative methods were 
developed to determine the urinary PAGN levels by using 
UPLC-UV. The urinary level of PAGN, measured relative 
to creatinine (Cr), was significantly elevated in IC patients 
(mean 0.47mg/mg Cr) compared with BC (bacterial 
cystitis) patients (mean 0.25mg/mg Cr) and HVs (healthy 
volunteers) (mean 0.11mg/mg Cr). Interestingly, urinary 
PAGN/Cr ratios in patients with mild IC (grade I) and 
moderate IC (grade II) were higher than for patients with 
severe IC (grade III). Moreover, urinary PAGN/Cr ratios 
with mild and moderate IC patients (mean 0.30mg/mg Cr) 
were higher than HVs (mean 0.059mg/mg Cr), in the 
validation set. These findings establish urinary PAGN/Cr 
ratios as a novel urinary marker of IC, and may contribute 
to early diagnosis of IC patients [39]. 
Another recent study [40] aims to investigate the 
molecular signatures underlying bladder pain 
syndrome/interstitial cystitis (BPS/IC) by using cDNA 
microarray. Microarray gene expression profiles are 
studied in a matched case-control study by using a 
system of conditional regression modeling. Main findings 
are summarized as it follows: firstly, a "139-gene" model 
was discovered to contain high expressions of bladder 
epithelium, which feature in BPS/IC. Secondly, complex 
metabolic reactions, including carbohydrate, lipid, 
cofactors, vitamins, xenobiotics, nucleotide, and amino 
acid metabolisms, are found to have a strong relationship 
with bladder smooth muscle contraction through IC status. 
Thirdly, it was found that the transcriptional regulations of 
IC-induced bladder smooth muscle contraction status, 
including the level of contractile force, tissue homeostasis, 
energy homeostasis, and the development of nervous 
system. In addition, this study suggested that the mast-
cell activation mediated by the high-affinity receptor of Fc 
episilon RI triggers allergic inflammation through IC 
status. Such genetic changes, jointly termed "bladder 
remodeling" can constitute an important long-term 
consequence of phosphate-buffered saline (PBS)/IC. The 
success of this innovation has supported the use of 
microarray-based expression profiling as a single 
standardized platform for diagnosis of PBS/IC and 
offering drug discovery. 
Examining the urinary bladder mucosa with a 
flexible cystoscope with the NBI system makes it possible 
to easily detect ulcers of bladder mucosa and areas with 
angiogenesis. Therefore, it is considered that the use of a 
flexible cystoscope with the NBI system is highly practical 
for the IC/PBS diagnosis [41]. 
 
New directions in PBS/IC treatment 
One study evaluated the safety and efficacy of 
intravesical liposomes, a mucosal protective agent, 
compared to oral pentosan polysulfate sodium for 
interstitial cystitis/painful bladder syndrome [43]. A 
prospective longitudinal study was performed as a result 
of the effect of 2 independent treatments (intravesical 
liposomes and oral pentosan polysulfate sodium) in 
patients with interstitial cystitis/painful bladder syndrome. 
Ten possible responses (or measures) to treatment were 
monitored at three time points, including baseline, and 
weeks 4 and 8. A total of 24 patients with interstitial 
cystitis/painful bladder syndrome were evaluated in a 1:1 
ratio to intravesical liposomes (80 mg/40 cc distilled 
water) once weekly or to oral pentosan polysulfate sodium 
(100 mg) 3 times daily for 4 weeks each. No patient had 
urinary incontinence, retention or infection due to 
liposome instillation. There were no unanticipated adverse 
events and no significant worsening of symptoms during 
follow-up. Statistically significant decreases in urinary 
frequency and nocturia were observed in each treatment 
group. Statistically significant decreases in pain, urgency 
and the O'Leary-Sant symptom score were observed in 
the liposome group. Decreased urgency in the liposome 
group had the most profound effect of the ordinal 
measures. 
Each glycosaminoglycan directed treatment 
seemed beneficial. Liposome intravesical instillation is 
safe for interstitial cystitis/painful bladder syndrome with 
potential improvement after 1 course of therapy for up to 8 
weeks. Intravesical liposomes achieved efficacy similar to 
that of oral pentosan polysulfate sodium. Further large-
scale placebo controlled studies are needed. Intravesical 
liposomes appear to be a promising new treatment for 
interstitial cystitis/painful bladder syndrome. 
  Another study compared the clinical 
effectiveness of type A botulinum toxin (BoNT-A) 
injections followed by hydrodistention (HD) with HD alone, 
in patients with interstitial cystitis/painful bladder 
syndrome (IC/PBS). A prospective, randomized study was 
performed in a urological referral centre [44]. In all, 67 
patients with IC/PBS who had failed conventional 
treatments were enrolled. Of these, 44 patients received 
suburothelial injection with 200U (15) or 100U (29) of 
BoNT-A followed by cystoscopic HD 2 weeks later (BoNT-
A groups). The control group (23 patients) received the 
identical HD procedure with no BoNT-A injection. All 
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patients remained on baseline medications of pentosan 
polysulphate throughout the study. Bladder pain visual 
analogue scale (VAS), O'Leary-Sant symptom and 
problem indexes, functional bladder capacity (FBC) and 
urodynamic variables were measured at baseline and 
after treatment. Global response assessment was used to 
evaluate successful treatment response.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IC/PBS symptom score significantly 
decreased in all three groups, but VAS reduction, 
FBC and cystometric bladder capacity increases 
were significant only in the BoNT-A groups at 3 
months. Out of the 44 patients in the BoNT-A group 
31 (71%) had a successful result at 6 months. A 
successful result at 12 and 24 months was reported 
in 24 (55%) and 13 (30%) patients in BoNT-A group, 
respectively, compared with only six (26%) and four 
(17%) in the control group (P = 0.002). Intravesical 
injections of BoNT-A followed by HD produced 
significantly better clinical results than HD alone in 
patients with IC/PBS. 
Intravesical Alkalinized Lidocaine (PSD597) 
Offers Sustained Relief from Symptoms of Interstitial 
Cystitis and Painful Bladder Syndrome. The aim of 
this study was to assess the immediate and 
sustained relief of the symptoms of interstitial 
cystitis/painful bladder syndrome (IC/PBlS) after a 
consecutive 5-day course of treatment with 
intravesical alkalinized lidocaine (PSD597), and to 
characterize the pharmacokinetics of single and 
multiple doses of intravesical PSD597 in a subgroup 
of patients. This preliminary study showed that 
PSD597 was effective in providing sustained 
amelioration of symptoms of IC/PBlS beyond the 
acute treatment phase. The drug was safe, well 
tolerated and devoid of the systemic side effects, 
often experienced with oral drug administration [45]. 
Intravesical Nanocrystalline Silver (NCS) 
Decreases Experimental Bladder Inflammation [46]. 
Boucher and co-workers from Boston and Dallas 
examined the effect of intravesical NCS in an established 
model of bladder inflammation by using protamine 
sulfate and lipopolysaccharide in the rat. Results showed 
that short intravesical treatment with 1% NCS 
significantly decreased protamine/lipopolysaccharide 
induced urine histamine, bladder explant tumor necrosis 
alpha-factor, and bladder inflammation including mast 
cell accumulation and degranulation. NCS inhibited 
histamine release immediately after pretreatment, but it 
inhibited the delayed tumor necrosis alpha-factor release 
even if given after the induction of the inflammatory 
response.    
Timely hyaluronan instillation therapy [47] 
may lead to complete symptom remission or even 
cure in part of the IC/PBS patients, while some 
responders need continuous intravesical therapy. 
The present results suggest that selection of patients 
for hyaluronan therapy by potassium testing 
improves the outcome of intravesical therapy with a 
response rate of >80%. 
Fig. 2 O’Leary-Sant Symptom Score 
Short-Term Results of Bilateral S2-S4 Sacral 
Neuromodulation are suitable in the Treatment of 
Refractory Interstitial Cystitis, Painful Bladder 
Syndrome, and Chronic Pelvic Pain [48]. The 
efficacy of bilateral caudal epidural sacral 
neuromodulation for the treatment of refractory 
chronic pelvic pain (CPP), painful bladder syndrome, 
and interstitial cystitis (IC) was evaluated. Thirty 
consecutive patients (21 females, 9 males) with 
severe refractory symptoms underwent bilateral S2-
S4 sacral neuromodulation for CPP/IC. The pain 
score improved by 40% (p = 0.04) and the UDI-6 
(Urogenital Distress Inventory) score by 26% (p = 
0.05). On average, patients reported a 42% 
improvement in their symptoms. SF-36 scores did 
not improve significantly. In refractory patients, 
bilateral caudal epidural sacral neuromodulation is 
another possible mode of treatment, which appears 
to improve both pelvic pain and voiding symptoms. 
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